Mark Alvino Sells 13,093 Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 13,093 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the completion of the transaction, the director owned 77,252 shares of the company's stock, valued at approximately $452,696.72. This trade represents a 14.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mark Alvino also recently made the following trade(s):

• On Tuesday, May 27th, Mark Alvino sold 2,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $6.38, for a total transaction of $12,760.00.
• On Friday, May 16th, Mark Alvino sold 8,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.68, for a total transaction of $45,440.00.

Abeona Therapeutics Trading Down 1.9%

Shares of Abeona Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $5.74. The stock had a trading volume of 774,254 shares, compared to its average volume of 701,588. The firm has a 50-day moving average of $6.01 and a two-hundred day moving average of $5.57. Abeona Therapeutics Inc. has a 12-month low of $3.93 and a 12-month high of $7.32. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. The firm has a market cap of $293.64 million, a P/E ratio of -4.52 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. Sell-side analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. HC Wainwright upped their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, April 30th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $19.00 price target for the company. Stifel Nicolaus reduced their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Finally, Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $19.25.

Institutional Trading of Abeona Therapeutics

Several hedge funds have recently made changes to their positions in ABEO. Adage Capital Partners GP L.L.C. grew its stake in shares of Abeona Therapeutics by 20.1% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after buying an additional 652,366 shares during the period. Western Standard LLC grew its stake in shares of Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock valued at $11,610,000 after buying an additional 386,321 shares during the period. Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after buying an additional 118,262 shares during the period. 683 Capital Management LLC boosted its position in shares of Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock worth $4,411,000 after purchasing an additional 116,845 shares during the period. Finally, Newtyn Management LLC boosted its position in shares of Abeona Therapeutics by 26.3% during the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after purchasing an additional 100,000 shares during the period. Hedge funds and other institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.